How did the CSL share price escape the carnage today?

Could shares in the ASX healthcare company be in for a better ride?

Key points
  • The CSL share price finished in the green today 
  • The company's shares jumped by more than 2% before retreating 
  • Analysts have named CLS as a share to buy in volatile times 

The S&P/ASX 200 Index (ASX: XJO) may have slipped today, but the CSL Ltd (ASX: CSL) share price had a better day.

CSL shares jumped 0.84% to $270.40. In comparison, the benchmark index dropped 1.18% today.

So what is happening at CSL?

Happy healthcare workers in a lab.

Image source: Getty Images

How is the CSL share price performing?

Shares in the global biotech company jumped 2.15% in earlier trade to $273.95 before retreating to the current share price. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) also leapt more than 1% in early trade from 40,260 to 40,683 points before pulling back.

Analysts at Wilsons have recently named CSL as one of four "defensive growth" shares to buy in turbulent times.

In a memo to clients, Wilsons recommended it was "sensible" to have an above-average allocation to defensives including CSL:

Our picks are healthcare, insurance and telco.

Sectors like healthcare and consumer staples, along with utilities, have performed well against a backdrop of higher uncertainty around the US Fed's and RBA's hiking expectations and the impact this will have on the economy.

Wilsons also recommended Insurance Australia Group Ltd (ASX: IAG), Telstra Corporation Ltd (ASX: TLS) and Healthco Healthcare and Wellness REIT (ASX: HCW).

Meanwhile, Macquarie has also recently named CSL as a share to buy during market volatility. My Foolish colleague Brendon reported that CSL is considered by Macquarie to be a COVID-recovery share.

Share price snapshot

The CSL share price has fallen nearly 2% in the past 12 months while it has descended 7% year-to-date.

In comparison, the benchmark ASX 200 has returned less than 1% over the past year.

CSL has a market capitalisation of nearly $130 billion based on today's share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »